Absci initiated with a Buy at Needham

Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its practical approach” to drug development, the analyst tells investors in a research note. The firm says the company has “potential best-in-class assets in high value therapeutic spaces” and a business approach focused on early stage value creation and monetization. Absci entered 2025 with several ongoing early stage and clinical programs, adds Needham.